Constellation Pharmaceuticals Raises $15M in Series B Financing
Constellation Pharmaceuticals, Inc., a Cambridge, MA-based biopharmaceutical company in the field of epigenetics, has raised $15m in a Series B extension financing.
Investors include existing shareholders Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.
The company intends to use the funds to continue to advance product candidates in its portfolio toward clinical development.
Led by President and CEO Mark A. Goldsmith, M.D., Ph.D., Constellation Pharmaceuticals focuses on the discovery and development of small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory/immunologic disorders.